Close Menu

NEW YORK – In a document filed with the US Securities and Exchange Commission on Wednesday, Progenity said that it is trimming its workforce by around 10 percent and revealed that a commercial insurer is seeking recoupment of $27.4 million from the firm in alleged overpayments.

The company it is terminating approximately 67 employees, who will exit before the end of this year. The termination benefits will cost the company $1.3 million, it noted.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.